Bifogade filer
BICO Group AB has settled its convertible bonds
Kurs
+1,66%
Likviditet
3,42 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-11-11 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2026-08-19 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-08 | N/A | X-dag ordinarie utdelning BICO 0.00 SEK |
| 2026-05-07 | N/A | Årsstämma |
| 2026-04-29 | 07:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-18 | - | Bokslutskommuniké 2025 |
| 2025-11-04 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-19 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-09 | - | X-dag ordinarie utdelning BICO 0.00 SEK |
| 2025-05-08 | - | Årsstämma |
| 2025-04-29 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-19 | - | Bokslutskommuniké 2024 |
| 2024-11-26 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-20 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-21 | - | X-dag ordinarie utdelning BICO 0.00 SEK |
| 2024-05-20 | - | Årsstämma |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-20 | - | Bokslutskommuniké 2023 |
| 2023-11-14 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-10 | - | X-dag ordinarie utdelning BICO 0.00 SEK |
| 2023-05-09 | - | Årsstämma |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-22 | - | Bokslutskommuniké 2022 |
| 2022-12-14 | - | Extra Bolagsstämma 2022 |
| 2022-11-09 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-18 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-27 | - | X-dag ordinarie utdelning BICO 0.00 SEK |
| 2022-04-26 | - | Årsstämma |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-11-17 | - | Extra Bolagsstämma 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-27 | - | X-dag ordinarie utdelning BICO 0.00 SEK |
| 2021-04-26 | - | Årsstämma |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-12-18 | - | X-dag ordinarie utdelning BICO 0.00 SEK |
| 2020-12-17 | - | Extra Bolagsstämma 2020 |
| 2020-10-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-04-09 | - | Kvartalsrapport 2020-Q2 |
| 2020-01-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-01-10 | - | Split BICO 1:4 |
| 2019-12-19 | - | X-dag ordinarie utdelning BICO 0.00 SEK |
| 2019-12-18 | - | Årsstämma |
| 2019-10-24 | - | Bokslutskommuniké 2019 |
| 2019-08-26 | - | Extra Bolagsstämma 2019 |
| 2019-07-11 | - | Kvartalsrapport 2019-Q3 |
| 2019-04-10 | - | Kvartalsrapport 2019-Q2 |
| 2018-12-14 | - | X-dag ordinarie utdelning BICO 0.00 SEK |
| 2018-12-13 | - | Årsstämma |
| 2018-10-24 | - | Bokslutskommuniké 2018 |
| 2018-07-11 | - | Kvartalsrapport 2018-Q3 |
| 2018-04-11 | - | Kvartalsrapport 2018-Q2 |
| 2018-01-17 | - | Kvartalsrapport 2018-Q1 |
| 2017-12-15 | - | X-dag ordinarie utdelning BICO 0.00 SEK |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
BICO Group AB (publ) ("BICO" or the "Company") announces that its outstanding convertible bonds (ISIN: XS2319958208) have today been settled in full on their scheduled maturity date.
The convertible bonds, with a total outstanding principal amount of SEK 1,008 million, have been repaid at par value in accordance with the terms and conditions of the instrument. Following today's settlement, no convertible bonds under this ISIN remain outstanding.
The redemption follows the Company's successful issuance of EUR 40 million senior secured bonds, as announced on 28 January 2026. Together with the new bond issuance, BICO is well-positioned with a robust balance sheet and strong financial preparedness going forward.
For further information, please contact:
Jacob Thordenberg, BICO Group AB
Phone: +46 735 34 88 84
E-mail: jt@bico.com
The information was submitted for publication, through the agency of the contact person set out above on March 18, 2026, at 8.15am CET.
About BICO
BICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 53,600+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 12,900 publications. Operating through two business areas – Lab Automation and Life Science Solutions – BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com